In Professor’s little helper in the 20 December 2007 issue of Nature, Barbara Sahakian and Sharon Morein-Zamir raise the question of whether “cognitive-enhancing” drugs like the methylphenidate I depend on (see previous) should be more readily available. Although they argue the positive side, they are still coming from the perspective that, well, of course any access to such drugs will be under the supervision of healthcare professionals. I don’t think we need “kindler gentler” gatekeepers.

If I Were King, adults would be able to choose their own advisors, do their own research, and make their own decisions.